General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
GameStop Stock Plunges Despite Optimistic Outlook from Roaring Kitty | news.google.com • |
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team | accesswire.com • |
Stock market outlook: A wall of money to drive stocks to record highs | news.google.com • |
Lululemon stock surges after company boosts profit outlook, stock buybacks | news.google.com • |
Cheap or Chump? The Outlook Is Dim for Intel Stock. | news.google.com • |
India Stock Market Outlook June 2024 – Forbes Advisor INDIA | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -0.88 | -1.55 | -0.67 | -76.14% |
2024-02-14 | 2023-12 | -1 | -0.8 | 0.2 | 20.00% |
2023-12-22 | 2023-09 | -1 | -1 | N/A | N/A |
2023-08-14 | 2023-06 | -0.8 | -1.6 | -0.8 | -100.00% |
2023-05-15 | 2023-03 | -1.2 | -0.6 | 0.6 | 50.00% |
2023-02-14 | 2022-12 | -0.8 | -1.6 | -0.8 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Chardan Capital | Downgrade | Buy | Neutral |
2023-08-30 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-08-29 | Brookline Capital | Downgrade | Buy | Hold |
2023-08-29 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-08-29 | BTIG | Downgrade | Buy | Neutral |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-04-19 | DAGNON TERRY | Chief Operating Officer | 653.06K | Sale |
2024-03-06 | EVANSON JEFF | Officer | 808.46K | Purchase |
2024-03-27 | HADDADIN YEZAN MUNTHER | Director | 5.05K | Purchase |
2022-10-04 | HILZINGER KURT J | Director | 473.12K | Purchase |
2021-04-19 | KENYON LAWRENCE A. | Chief Executive Officer | 18.93K | Purchase |
2022-10-06 | SUKHTIAN FAISAL GHIATH | Director | 68.00K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.22M | 16.04M | 3.54% |
2023-06-29 | Vanguard Group Inc | 6.15M | 10.70M | 2.36% |
2023-06-29 | State Street Corporation | 2.75M | 4.79M | 1.06% |
2023-06-29 | Geode Capital Management, LLC | 2.72M | 4.73M | 1.05% |
2023-06-29 | Northern Trust Corporation | 1.26M | 2.18M | 0.48% |
2023-06-29 | Nuveen Asset Management, LLC | 598.96K | 1.04M | 0.23% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.61M | 6.28M | 1.39% |
2023-08-30 | iShares Russell 2000 ETF | 3.58M | 815.24K | 1.37% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.45M | 2.52M | 0.56% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.38M | 2.38M | 0.53% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.27M | 289.29K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 519.75K | 779.62K | 0.20% |
Split | Date |
---|---|
1 : 20 | 2024-03-14 |
1 : 8 | 2019-03-18 |
Frank, I told you to cover …. Now you are losing even more money. We all know your loses make you cranky and then you take out on us. Get out with what you have left and be happy for others being successful
I suspect that “shorts” will get real aggressive in the coming months…especially with positive news and low volume….(EMA…Norse 7…clear path with FDA)..as they lose money they will say the stock is garbage and start calling people clowns. Feel sorry for these “short sided” folks.
Frank, you can’t be a dick when you post and expect anyone to think you are looking out for anyone but yourself. Based on what I know of you and historical posts…. You are not doing that very well either. Here is a clue. EMA has written guidelines different from FDA. Outlook has more than enough studies to get approval there. Then UK and Japan etc….
USA will be the last to approve. Not because it won’t get done. Based on the power and statistical significance the next study will pass as well or the whole point of statistics will be a big pie in the FDA face. The delay was a non thought out policy of bureaucracy. This is something the rest of the world doesn’t suffer from
Frank, I won’t block you are my favorite comedian.
Frank, let me help you. The decimal goes here $10.00. Take your crystal ball back clearly it is broken. The only place this stock is .10 is your wet dreams. You should have sold in the twenty’s . Cover your short sell before you lose it all.
Frank, you are funny…. You make me laugh!
Just reviewed requirements for approval in EMA. It looks like an easy shoe in. There are other markets that we can sell in until FDA is ready. Just to name a few EMA, UK, Japan and the list goes on and on. Remember it is a global market and the FDA is only a piece of it.
Frank, we all know you sold short at $1.70. You held because you said it would go to .10 cents. We are not clowns because you are losing money. Take some advice and cover your short and get out. Don’t eat your pride lose all your money.
Clueless Frank is spouting off again. He never talks about the money he is losing every time the price goes up. If he had a reliable crystal ball he would have left when the stock hit .2 cents. Now we only hear from him as he crystal in his beer over the loses. Poor poor Frank!
Will we see a Norse 7 extension trial looking at long term efficacy? May even provide evidence for two more disease states🧐
Best news!!! Clear path with FDA, CMC issues resolution for product. All this information will help with EMA approval in Europe in a few months. Remember that FDA is only one market in the world. Next quarter approval in Europe and in 2025 the world. By then the world market will be 19 billion in annual sales. This molecule. Currently takes half. Don’t worry about dissolution talk. There is plenty of money here to make all share holder rich.
Frank, you have no imagination. We all know you are losing money every time the stock goes up. Calling the longs names every time you are losing money does go well in Gain respect.
There won’t be bad news after the meeting. We will find out when we start making money in a few months or a year. Either way this molecule is being used TODAY in a dirty form off label in 13 going to 19 billion dollar market. After two decades of off label use do you think doctors would continue to put their medical license and personal money at risk if the safety and efficacy was not there for patients. A more pure version of this molecule to inject in the eye is in everyone’s best interest. Have patience. There’s a lot of money to be made here.
Frank,
You are a rookie at this and talk a lot of hot air. If you had any experience you would know that money can be made on the same stock going up or down. Now it is going up …. Deal with it.
Hawkeye, if a study is needed the Norse 7 study data is expected 1st qtr 2024.
Frank, did you know it costs 1 billion dollars to get a drug approved. Even if your worst case comes true. 1 billion divided by twice the the amount of shares today is a very very big windfall. This isn’t a Normal molecule getting approved for the first time. This exact same molecule has been used off label for over 2 decades with multiple studies done by the NIH and NEI all have shown efficacy and safety. The molecule is in current use right now for about 6 billion in sales annually. In the pharma world just hitting 1 billion is monumental. The FDA already know the molecule works the just shut down production at an off label plant for CMC issues. There is now a shortage and patients can’t even get the unpurified version. Waiting a year and seeing diluted 240 million shares still make me very rich. The problem here is you are short sighted with no business sense for the bigger picture
Frank, did you forget to take your medication this morning. Once again you are making predictions and taking credit things based on nothing but hot air.
Yes, I meant cents not dollars you get the drift. Still looking for an explanation.
Can anyone explain how 99% of tradable shares sold over $60 and less than 8 hours later someone is dumb enough to sell in the 50s? 🧐